메뉴 건너뛰기




Volumn 26, Issue 10, 2011, Pages 1467-1469

Effects of statins on cholestasis: Good, bad or indifferent?

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID; CARRIER PROTEIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR ALPHA; MESSENGER RNA; ORGANIC SOLUTE TRANSPORTER ALPHA; ORGANIC SOLUTE TRANSPORTER BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRAVASTATIN; PREGNANE X RECEPTOR; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

EID: 80053124083     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06836.x     Document Type: Editorial
Times cited : (6)

References (26)
  • 1
    • 0036251569 scopus 로고    scopus 로고
    • Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs
    • Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin. Liver Dis. 2002; 22: 169-83.
    • (2002) Semin. Liver Dis. , vol.22 , pp. 169-183
    • Chitturi, S.1    George, J.2
  • 2
    • 7744220837 scopus 로고    scopus 로고
    • Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits
    • Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr. Metab. Cardiovasc. Dis. 2004; 14: 215-24.
    • (2004) Nutr. Metab. Cardiovasc. Dis. , vol.14 , pp. 215-224
    • Anfossi, G.1    Massucco, P.2    Bonomo, K.3    Trovati, M.4
  • 5
    • 0037013571 scopus 로고    scopus 로고
    • Cholestasis associated with the use of pravastatin sodium
    • Batey RG, Harvey M. Cholestasis associated with the use of pravastatin sodium. Med. J. Aust. 2002; 176: 561-3.
    • (2002) Med. J. Aust. , vol.176 , pp. 561-563
    • Batey, R.G.1    Harvey, M.2
  • 7
    • 58149507709 scopus 로고    scopus 로고
    • Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report
    • Rahier JF, Rahier J, Leclercq I, Geubel AP. Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol. Belg. 2008; 71: 318-20.
    • (2008) Acta Gastroenterol. Belg. , vol.71 , pp. 318-320
    • Rahier, J.F.1    Rahier, J.2    Leclercq, I.3    Geubel, A.P.4
  • 8
    • 0035991457 scopus 로고    scopus 로고
    • Acute cholestatic hepatitis after reinitiating treatment with atorvastatin
    • Ridruejo E, Mando OG. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J. Hepatol. 2002; 37: 165-6.
    • (2002) J. Hepatol. , vol.37 , pp. 165-166
    • Ridruejo, E.1    Mando, O.G.2
  • 10
    • 77954424607 scopus 로고    scopus 로고
    • Statins in primary biliary cirrhosis: are they safe?
    • Rajab MA, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig. Dis. Sci. 2010; 55: 2086-8.
    • (2010) Dig. Dis. Sci. , vol.55 , pp. 2086-2088
    • Rajab, M.A.1    Kaplan, M.M.2
  • 11
    • 77049089696 scopus 로고    scopus 로고
    • Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment
    • Stojakovic T, Thierry C, Putz-Bankuti C etal. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010; 209: 178-83.
    • (2010) Atherosclerosis , vol.209 , pp. 178-183
    • Stojakovic, T.1    Thierry, C.2    Putz-Bankuti, C.3
  • 12
    • 0027370470 scopus 로고
    • Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia
    • Kurihara T, Akimoto M, Abe K etal. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin. Ther. 1993; 15: 890-8.
    • (1993) Clin. Ther. , vol.15 , pp. 890-898
    • Kurihara, T.1    Akimoto, M.2    Abe, K.3
  • 13
    • 0029055416 scopus 로고
    • Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis
    • Kamisako T, Adachi Y. Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am. J. Gastroenterol. 1995; 90: 1187-8.
    • (1995) Am. J. Gastroenterol. , vol.90 , pp. 1187-1188
    • Kamisako, T.1    Adachi, Y.2
  • 14
    • 0036102527 scopus 로고    scopus 로고
    • Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers
    • Ritzel U, Leonardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J. Hepatol. 2002; 36: 454-8.
    • (2002) J. Hepatol. , vol.36 , pp. 454-458
    • Ritzel, U.1    Leonardt, U.2    Nather, M.3    Schafer, G.4    Armstrong, V.W.5    Ramadori, G.6
  • 15
    • 48349115722 scopus 로고    scopus 로고
    • Treatment of hypercholesterolemia in patients with primary biliary cirrhosis may be more beneficial than indicated
    • Balmer ML, Dufour J-F. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis may be more beneficial than indicated. Swiss Med. Wkly. 2008; 138: 415-19.
    • (2008) Swiss Med. Wkly. , vol.138 , pp. 415-419
    • Balmer, M.L.1    Dufour, J.-F.2
  • 16
    • 44449143344 scopus 로고    scopus 로고
    • Atorvastatin does not improve liver biochemistries or Mayo risk score in primary biliary cirrhosis
    • Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer H, Odin JA. Atorvastatin does not improve liver biochemistries or Mayo risk score in primary biliary cirrhosis. Dig. Dis. Sci. 2008; 53: 1988-93.
    • (2008) Dig. Dis. Sci. , vol.53 , pp. 1988-1993
    • Stanca, C.M.1    Bach, N.2    Allina, J.3    Bodian, C.4    Bodenheimer, H.5    Odin, J.A.6
  • 17
    • 34548758431 scopus 로고    scopus 로고
    • Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid
    • Stojakovic T, Putz-Bankuti C, Fauler G etal. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46: 776-84.
    • (2007) Hepatology , vol.46 , pp. 776-784
    • Stojakovic, T.1    Putz-Bankuti, C.2    Fauler, G.3
  • 18
    • 3042620358 scopus 로고    scopus 로고
    • Cholestasis: human disease and experimental animal models
    • Rodriguez-Garay EA. Cholestasis: human disease and experimental animal models. Ann. Hepatol. 2003; 2: 150-8.
    • (2003) Ann. Hepatol. , vol.2 , pp. 150-158
    • Rodriguez-Garay, E.A.1
  • 19
    • 77951561501 scopus 로고    scopus 로고
    • Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis
    • Wagner M, Zollner G, Trauner M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis. 2010; 30: 160-77.
    • (2010) Semin. Liver Dis. , vol.30 , pp. 160-177
    • Wagner, M.1    Zollner, G.2    Trauner, M.3
  • 20
    • 77950851232 scopus 로고    scopus 로고
    • Effect of rosuvastatin on cholestasis-induced hepatic injury in rat livers
    • Awad AS, Kamel R. Effect of rosuvastatin on cholestasis-induced hepatic injury in rat livers. J. Biochem. Mol. Toxicol. 2010; 24: 89-94.
    • (2010) J. Biochem. Mol. Toxicol. , vol.24 , pp. 89-94
    • Awad, A.S.1    Kamel, R.2
  • 22
    • 33846585018 scopus 로고    scopus 로고
    • Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis
    • Demirbilek S, Tas E, Gurunluoglu K etal. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Pediatr. Surg. Int. 2007; 23: 155-62.
    • (2007) Pediatr. Surg. Int. , vol.23 , pp. 155-162
    • Demirbilek, S.1    Tas, E.2    Gurunluoglu, K.3
  • 23
    • 79958263832 scopus 로고    scopus 로고
    • Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease
    • Claudel T, Zollner G, Wagner M, Trauner M. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim. Biophys. Acta 2011; 1812: 867-78.
    • (2011) Biochim. Biophys. Acta , vol.1812 , pp. 867-878
    • Claudel, T.1    Zollner, G.2    Wagner, M.3    Trauner, M.4
  • 24
    • 79952227694 scopus 로고    scopus 로고
    • Nuclear receptors in liver disease
    • Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology 2011; 53: 1023-34.
    • (2011) Hepatology , vol.53 , pp. 1023-1034
    • Wagner, M.1    Zollner, G.2    Trauner, M.3
  • 25
    • 79953173235 scopus 로고    scopus 로고
    • Nuclear receptors as new perspective for the management of liver diseases
    • Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120-5.
    • (2011) Gastroenterology , vol.140 , pp. 1120-1125
    • Trauner, M.1    Halilbasic, E.2
  • 26
    • 80053099585 scopus 로고    scopus 로고
    • Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis
    • Kolouchova G, Brcakova E, Hirsova P etal. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis. J. Gastroenterol. Hepatol. 2011; 26: 1544-51.
    • (2011) J. Gastroenterol. Hepatol. , vol.26 , pp. 1544-1551
    • Kolouchova, G.1    Brcakova, E.2    Hirsova, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.